Oxidative-stress and long-term hepatotoxicity: comparative study in Upcyte human hepatocytes and hepaRG cells.
Autores de IIS La Fe
Grupos
Abstract
Drug-induced liver injury (DILI) is one of the most common and serious adverse drug reactions and a major cause of drug development failure and withdrawal. Although different molecular mechanisms are implicated in DILI, enhanced ROS levels have been described as a major mechanism. Human-derived cell models are increasingly used in preclinical safety assessment because they provide quick and relatively inexpensive information in early stages of drug development. We have analyzed and compared the phenotype and functionality of two liver cell models (Upcyte human hepatocytes and HepaRG cells) to demonstrate their suitability for long-term hepatotoxicity assessments and mechanistic studies. The transcriptomic and functional analysis revealed the maintenance of phase I and phase II enzymes, and antioxidant enzymes along time in culture, although the differences found between both test systems underlie the differential sensitivity to hepatotoxins. The evaluation of several mechanisms of cell toxicity, including oxidative stress, by high-content screening, demonstrated that, by combining the stable phenotype of liver cells and repeated-dose exposure regimes to 12 test compounds at clinically relevant concentrations, both Upcyte hepatocytes and HepaRG offer suitable properties to be used in routine screening assays for toxicological assessments during drug preclinical testing.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Datos de la publicación
- ISSN/ISSNe:
- 0340-5761, 1432-0738
- Tipo:
- Article
- Páginas:
- 1021-1037
- Factor de Impacto:
- 1,100 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
ARCHIVES OF TOXICOLOGY SPRINGER HEIDELBERG
Citas Recibidas en Web of Science: 7
Documentos
- No hay documentos
Filiaciones
Keywords
- Functionality; Hepatotoxicity; High-content screening; Liver cell model; Oxidative stress; ROS levels
Proyectos asociados
DESARROLLO DE UN MODELO HEPATOCELULAR HUMANO DIFERENCIADO PARA ESTUDIOS DE METABOLISMO Y POTENCIAL INDUCTOR DE NUEVOS FARMACOS
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
SAF2003-09353 . 2003
DEVELOPMENT OF A HIGH THROUGHPUT GENOMICS-BASED TEST FOR ASSESSING GENOTOXIC AND CARCINOGENIC PROPERTIES OF CHEMICAL COMPOUNDS IN VITRO
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
CARCINOGENOMICS . COMISION EUROPEA . 2006
MECANISMOS TRNACRIPCIONALES IMPLICADOS EN LA ETIOLOGIA DEL HIGADO GRASO NO ALCOHOLICO. ESTUDIOS EN UN MODELO CELULAR HUMANO DE ESTEATOSIS Y APLICACION AL TRANSPLANTE DE HEPATOCITOS EN TERAPIA CELULAR.
Investigador Principal: RAMIRO JOVER ATIENZA
PI07/0550 . INSTITUTO DE SALUD CARLOS III . 2007
MECANISMOS TRANSCRIPCIONALES IMPLICADOS EN EL HIGADO GRASO NO ALCOHOLICO DE ORIGEN METABOLICO E IATROGENICO: INFLUENCIA DE LA RESISTENCIA A LA INSULINA
Investigador Principal: RAMIRO JOVER ATIENZA
PI10/00194 . INSTITUTO DE SALUD CARLOS III . 2010
METABONOMICA Y CITOMICA COMO NUEVOS PARADIGMAS Y ESTRATEGIAS EXPERIMENTALES PARA EL ESTUDIO DE LOS MECANISMOS DE HEPATOTOXICIDAD DE FARMACOS, PREDICCION DE SU POTENCIAL HEPATOTOXICO Y LA TRANSICION DE HEPATITIS I ATROGENICA A AUTOINMUNE.
Investigador Principal: MARÍA TERESA DONATO MARTÍN
PI10/00923 . INSTITUTO DE SALUD CARLOS III . 2010
AYUDA PREDOCTORAL DE FORMACION EN INVESTIGACION
Investigador Principal: MARÍA TERESA DONATO MARTÍN
FI11/00233 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2011
APROXIMACIONES METABONÓMICAS PARA EL ESTUDIO DE LA HEPATOTOXICIDAD IDIOSINCRÁSICA CON BASE METABÓLICA Y LA IDENTIFICACIÓN DEL AGENTE CAUSAL.
Investigador Principal: MARÍA TERESA DONATO MARTÍN
PI13/00986 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
HEPATOTOXICIDAD IDIOSINCRÁSICA POR FÁRMACOS: ESTRATEGIAS IN VITRO PARA DIAGNÓSTICO RETROSPECTIVO, ATRIBUCIÓN DE LA CAUSALIDAD Y EVALUACIÓN DEL POTENCIAL RIESGO CLÍNICO EN PACIENTES SUSCEPTIBLES.
Investigador Principal: MARÍA TERESA DONATO MARTÍN
PI16/00333 . INSTITUTO DE SALUD CARLOS III . 2017
EUTOXRISK21. AN INTEGRATED EUROPEAN ‘FLAGSHIP’ PROGRAM DRIVING MECHANISM-BASED.
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
681002_EUTOXRISK_CASTELL_H2020-PHC-33-2015 . COMISION EUROPEA . 2016
Evaluación preclínica de nuevas fuentes celulares y biomateriales en terapia celular para el tratamiento metabolopatías congénitas y fallo hepático.
Investigador Principal: LAIA TOLOSA PARDO
PI18/00993 . INSTITUTO DE SALUD CARLOS III . 2019
Tu hospital investiga RRI.
Investigador Principal: ANA ISABEL JUAN ROCH
FCT-18-14018 . FUNDACION ESPAÑOLA PARA LA CIENCIA Y LA TECNOLOGIA . 2019
IMPROVING FEASIBILITY OF LIVER CELL THERAPY: NEW CELL SOURCES AND STRATEGIES TO IMPROVE THE CLINICAL OUTCOME. (PROYECTO)
Investigador Principal: LAIA TOLOSA PARDO
CP16/00097 . INSTITUTO DE SALUD CARLOS III . 2017
ESTANCIA DE PERSONAL INVESTIGADOR DOCTOR EN CENTROS DE INVESTIGACION RADICADOS FUERA DE LA COMUNIDAD VALENCIANA. Laia Tolosa Pardo
Investigador Principal: LAIA TOLOSA PARDO
BEST2020/144 . CONSELLERIA DE EDUCACION . 2020
Nuevas tecnologías traslacionales para el tratamiento de enfermedades hepáticas: preacondicionamiento del hígado, nuevas fuentes celulares y biomateriales en terapia celular.
Investigador Principal: LAIA TOLOSA PARDO
PI21/00223 . INSTITUTO DE SALUD CARLOS III . 2022
Characterisation of human variability in Toxicodynamics: towards the development of quantitative Adverse Outcome Pathways (qAOPs).
Investigador Principal: LAIA TOLOSA PARDO
OC/EFSA/SCER/2021/03 . EUROPEAN FOOD SAFETY AUTHORITY . 2021
Cita
Donato MT,Jiménez N,Pelechá M,Tolosa L. Oxidative-stress and long-term hepatotoxicity: comparative study in Upcyte human hepatocytes and hepaRG cells. Arch Toxicol. 2022. 96. (4):p. 1021-1037. IF:6,100. (1).